Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Est. Enrollment: 65 participants
Study Start Date: Nov 18, 2019
Study Completion Date: Nov 01, 2035
Age: 18+ years
Gender: All
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.